All In Biotech

Drug Trial Radar · NCT02460159

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

A Phase III, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Atorvastatin Calcium Monotherapy

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Jun 23, 2015

Primary completion

Dec 22, 2016

Study completion Dec 22, 2016

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jun 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Atorvastatin up to 20 mg. There is no formal hypothesis for the study.

Conditions

  • Hypercholesterolemia
  • Heterozygous Familial Hypercholesterolemia

Interventions

  • EZ 10 mg/Atorva 20 mg FDCDrug

  • EZ 10 mg/Atorva 10 mg FDCDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experience 1 or More Adverse Event (AE)Time frame: up to 54 Weeks
  2. Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEsTime frame: up to 54 weeks
  3. Percentage of Participants Who Experience 1 or More Gallbladder-related AEsTime frame: up to 54 weeks
  4. Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEsTime frame: up to 54 weeks
  5. Percentage of Participants Who Experience 1 or More Hepatitis-related AEsTime frame: up to 54 weeks
  6. Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)Time frame: up to 52 weeks
  7. Percentage of Participants Who Experience Elevations in ALT or AST ≥5 Times ULNTime frame: up to 52 weeks
  8. Percentage of Participants Who Experience Elevations in ALT or AST ≥10 Times ULNTime frame: up to 52 weeks
  9. Percentage of Participants With Potential Hy's Law ConditionTime frame: up to 52 weeks
  10. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULNTime frame: up to 52 weeks
  11. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle SymptomsTime frame: up to 52 weeks
  12. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle SymptomsTime frame: up to 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.